Development of SARS-CoV-2 as a viral vector: A novel intranasal bivalent vaccine for SARS-CoV-2 and RSV
Science Advances · 2025
DOI: 10.1126/sciadv.adx7487 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Jiayu Xu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Respiratory Syncytial Virus, Human, Genetic Vectors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Negative-sense RNA viruses have been widely used as viral vectors for vaccine delivery. However, little is known about coronaviruses as vectors for delivering vaccines. Here, we have developed safe SARS-CoV-2 Omicron JN.1–based live attenuated vaccine candidates by combining a mutation (D130A) in the viral nsp16 protein, deletion of the furin cleavage site (dFCS) in the spike protein, deletion of accessory proteins, and/or modification of the transcription regulatory sequences (mTRS). Subsequently, using rJN.1, rJN.1-D130A-dFCS, and rJN.1-mTRS-D130A-dFCS as the backbones, we generated three recombinant viruses expressing a nonfunctional, soluble, and stabilized prefusion F protein of human respiratory syncytial virus (RSVF). Among them, rJN.1-D130A-dFCS-RSVF virus was sufficiently attenuated and highly immunogenic, providing complete protection against challenge with both JN.1 and RSV in hamsters. However, rJN.1-mTRS-D130A-dFCS-RSVF was poorly immunogenic. Collectively, we demonstrate that attenuated SARS-CoV-2 is an effective viral vector for delivering RSV vaccine, warranting further development as a novel intranasal bivalent vaccine for SARS-CoV-2 and RSV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.
- Center for Microbe and Immunity Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
- Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH, USA.
- Infectious Disease Institute, The Ohio State University, Columbus, OH, USA.
- Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, OH, USA.
- Center for RNA Biology, The Ohio State University, Columbus, OH, USA.
ORCID-Profile: Jiayu Xu, Michelle Chamblee, Fei Jiang, Mahesh Kc, Cheng Chih Hsu, Ilada Thongpan, Mohamed M Shamseldin, Heba M Amer, Amal O Amer, Prosper N Boyaka, Estelle Cormet-Boyaka, Mark E Peeples, Jianrong Li
Förderung
- NIAID NIH HHS
Zitieren
APA
Xu, J., Chamblee, M., Jiang, F., Kc, M., Hsu, C. C., Thongpan, I., Chen, P., Zhang, Y., Chiu, C. T., Shamseldin, M. M., Amer, H. M., Liang, X., Amer, A. O., Boyaka, P. N., Cormet-Boyaka, E., Peeples, M. E., & Li, J. (2025). Development of SARS-CoV-2 as a viral vector: A novel intranasal bivalent vaccine for SARS-CoV-2 and RSV. Science Advances. https://doi.org/10.1126/sciadv.adx7487
Vancouver
Xu J, Chamblee M, Jiang F, Kc M, Hsu CC, Thongpan I, et al. Development of SARS-CoV-2 as a viral vector: A novel intranasal bivalent vaccine for SARS-CoV-2 and RSV. Science Advances. 2025. doi:10.1126/sciadv.adx7487
BibTeX
@article{Xu2025,
author = {Xu, Jiayu and Chamblee, Michelle and Jiang, Fei and Kc, Mahesh and Hsu, Cheng Chih and Thongpan, Ilada and Chen, Phylip and Zhang, Yuexiu and Chiu, Chun-Ta and Shamseldin, Mohamed M and Amer, Heba M and Liang, Xueya and Amer, Amal O and Boyaka, Prosper N and Cormet-Boyaka, Estelle and Peeples, Mark E and Li, Jianrong},
title = {Development of SARS-CoV-2 as a viral vector: A novel intranasal bivalent vaccine for SARS-CoV-2 and RSV},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adx7487}
}
EUVIMED